Aims: To conduct a systematic review and meta-analysis of published observational evidence to assess the difference in the prevalence and progression of diabetic nephropathy, and the development of end-stage renal disease (ESRD) in people from three different ethnic groups with type 2 diabetes (T2DM).
| INTRODUCTION
Diabetes is a substantial public health problem and the most common cause of end-stage renal disease (ESRD) globally. The relative contribution of type 2 diabetes (T2DM) to the increasing burden of ESRD has been well established. 1, 2 With the rising epidemic of T2DM and obesity and an ageing population it is anticipated that the burden of renal disease on health systems will increase further.
A migrant is defined as someone who has either changed their usual country of residence or settled in another country such as the United States, Europe or Australia, or is a descendant of the former. 3 Globally migration is increasing, with the number of international migrants reaching 258 million in 2017. 4 A total of 79.6 million migrants originated from Asia and many of these were of South Asian origin, with 17 million originating from India alone. A total of 24.7 million of the migrants were of African origin, making Africa the fourth largest contributor to migration figures in 2017. 4 The 2011 UK Census showed an increase in the ethnic minority population. South Asian and African Caribbean migrants comprisẽ 8% and 3% of the total population in the UK, respectively. Together these ethnicities make up more than half of the United Kingdom's non-European population. 5 It is well established that South Asian and African Caribbean adults develop T2DM at a much younger age compared with their white counterparts, and exhibit a marked predisposition to cardiovascular disease and ESRD. 6, 7 In the United Kingdom, a higher incidence of central obesity and vascular disease has been reported in migrant
South Asian people when compared with white Europeans despite lower levels of cardiovascular risk factors. 7, 8 It is likely that higher levels of insulin resistance drive the higher rates of vascular disease and diabetes in this population. 9 A number of studies indicate that the risk of the development and progression of diabetic nephropathy varies among different populations. 8, 10, 11 The incidence of ESRD attributable to both Type 1 diabetes (T1DM) and T2DM is higher among South Asian than white European people. 12, 13 The literature on diabetic nephropathy in ethnic groups, however, is sparse and varied and it is not clear whether progression or higher levels of urine albumin excretion influence similar rates of estimated glomerular filtration rate (eGFR) decline among different ethnic populations, despite similar competing risks, and therefore may impact rates of prevalence of ESRD.
The objective of the present systematic review and meta-analysis was to examine and analyse published evidence on the prevalence of albuminuria, rates of disease progression and ESRD outcomes in white
European compared with South Asian and African Caribbean adults with nephropathy attributable to T2DM. We decided a priori that there were no differences in the prevalence and progression of diabetic nephropathy and the development of ESRD in various ethnicities with T2DM. (CENTRAL) and the Cochrane Renal Group trial register were searched using a broad search strategy to identify all potentially relevant publications for this review. Population search terms, including Medical Subject Heading (MeSH) "Asian Continental registry group," "Asians", Indians', "Pakistanis", "Bangladeshis", "Afro-Caribbeans" and "ethnic minority population" were combined with MeSH terms that covered T2DM, diabetes mellitus, nephropathy, renal disease, ESRD and albuminuria. Free text terms were also used to optimize search sensitivity. Reference lists were checked to identify any further articles. Studies were not limited to the English language, but none of the relevant studies required translation into English.
| Study selection
Only studies comparing the ethnicities white European, South Asian and African Caribbean, in whichever combination, in adult patients with T2DM and diabetic nephropathy were included. Where studies compared ethnicities other than those included in our selection criteria, data for South Asian, white European and African Caribbean participants were extracted separately. We excluded "American Asians" or "Asians" unless clearly defined, since they may comprise Arab, Chinese, Hmong, Lebanese, Turkish, Bangladeshi, Filipino, Indian, Korean, Pakistani or Taiwanese populations and therefore could not be categorized as South Asian or people originating from the Indian subcontinent. We used the term "African Caribbeans" to mean people of African descent wherever they are living in world.
Additionally, those studies that did not differentiate between T1DM and T2DM were only included if the estimated T2DM sample was ≥80% of the total sample. Because the review was aimed at identifying three key aspects of diabetic nephropathy, we grouped selected studies under "prevalence", "progression" and "outcomes studies".
Prevalence is defined as the number of cases existing at a given time in a given population usually expressed as a percentage. 14 Because the definition of "diabetic nephropathy" encompasses those with "incipient nephropathy", defined as the presence of microalbuminuria and those with "overt nephropathy", defined as those with macroalbuminuria or overt proteinuria, 15 we included all studies that measured either one or both of these outcomes in terms of prevalence of disease. Microalbuminuria and proteinuria were measured using different definitions across the majority of studies. In the present review, microalbuminuria was defined as an albumin creatinine ratio (ACR) of >2 mg/mmol and proteinuria as >30 mg/mmol. Prevalence studies carried out in a representative population and examining at least 50 participants or more were included in the review.
Progression studies included all studies that examined the progression/remission of albuminuria or estimated eGFR decline. Studies where progression was based on chronic kidney disease (CKD) stages 1-5, as defined by the National Kidney Foundation Disease Outcome Quality Initiative working group guidelines on the classification of CKD were included. Studies reporting the doubling of serum creatinine, or changes in creatinine clearance over time were also included in this review.
Outcome studies included any studies related to the development of ESRD, when the kidneys permanently fail to work as a result of diabetic nephropathy in patients with T2DM. The review was registered in PROSPERO (CRD42018107350).
| Review methods
The titles and abstracts of all articles identified by the broad literature search were assessed independently by two reviewers (C.J. and S.S.). Studies that did not meet inclusion criteria were discarded.
Full texts of selected articles were retrieved and assessed to determine if they met the inclusion criteria. A consensus was reached in case of any inconsistency with involvement of a third (K.K.). Those studies which met the inclusion criteria were included in the review and data were extracted independently using a standard data extraction form.
| Quality scoring of selected studies
We created a quality scoring system ranging from 0 to 6 points, based on parameters identified by the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. 16 We used four predefined domains, namely, selection criteria, measurement of exposure, objective diagnostic procedure and controlling for confounders, to assess the quality of the studies. Six points on this MOOSE scale reflects the highest study quality (Appendix S1).
| Statistical analysis
Pooled relative risks of microalbuminuria by ethnicity were estimated by fitting three random effects meta-analyses models. Heterogeneity between studies was assessed using the I 2 statistic. 17 For incidence of ESRD by ethnicity, data from studies was combined in a randomeffects meta-analysis model. Incidence was reported using incidence rate ratios (IRRs). In some studies the standard error of the IRR was calculated using a published formula. [18] [19] [20] Studies reporting hazard ratios, which can be assumed to estimations of the IRR, were also included in this review. As the impact of both age and duration of diabetes on the incidence of microalbuminuria may differ by ethnicity, we conducted meta-regression analyses to adjust for both these factors. This was done by extracting data on mean age and duration by ethnicity and calculating the difference in means between ethnic groups for each study. By fitting this difference in means in a metaregression model, the reported intercept will be the estimated incident rate ratio for ethnicity when the difference in mean age or duration is zero.
For all meta-analyses models fitted, funnel plots and Egger's tests were carried out to assess for publication bias. Since there was substantial heterogeneity attributable to large differences in clinical or methodological nature between the studies in terms of the reporting of the progression of diabetes nephropathy, we decided a priori not to pool the data on nephropathy progression from the studies in a meta-analysis. Instead, we did a narrative synthesis of the nephropathy progression in the studies. STATA release 15 (Stata Corp, College Station, Texas) was used for all statistical analyses.
| RESULTS
The search yielded a total of 2329 articles, of which 54 were retrieved for more detailed evaluation of the full text ( Figure 1 ). 
| Study quality
Quality scores for the 32 studies included in this review are shown in Table 1 . Overall, the quality of studies was high (median [interquartile range] score 5 [4] [5] [6] ), with 13 studies achieving the highest score.
| Prevalence of diabetes nephropathy
Data were extracted from 20 studies on prevalence of microalbuminuria in patients with T2DM by ethnic group ( Table 2 ). The study by 
| Progression of diabetes nephropathy
Five studies reported the progression of diabetic nephropathy (Table 3) . Three studies measured progression of disease in South Asian, white European and Afro Caribbean participants, 42, 44, 45 whereas two only compared progression in South Asian participants and white European participants. 39, 43 Three out of the five studies recorded annual eGFR decline. 44, 45 The remaining two studies assessed progression of renal disease by recording serial serum creatinine measurements, 43 assessing time taken for serum creatinine to double 42 and lastly measuring creatinine clearance over a set period of time. 39 In summary, in three of the studies, differences were noted in the progression of renal deterioration among the three ethnic groups, thus confirming the alternative hypothesis. Two studies showed no differences in the progression of renal deterioration.
Assessing the annual decline in eGFR, one study found a nonsignificant decline in Afro-Caribbean participants of −2.12 mL/min/1.73m 2 compared with white European participants (−1.93 mL/min/1.73m
and South Asian participants (−1.85 mL/min/1.73m 2 ). 44 The second study reported a significant difference in all three groups, with white in white European participants and 3.14 (95% CI 0.82, 5.46) in African
Caribbean participants (P < 0.05). 42 Finally, Koppiker et al. 43 compared the interaction between creatinine level and ethnicity using serum creatinine as a time-dependent variable. Results from extended
Cox modelling found a risk ratio of 1.00 (95% CI 0.99, 1.02) between
South Asian and white European participants. A meta-analysis was not performed because measurement of disease progression differed across the studies.
| End-stage renal disease
Ten studies reported the incidence of ESRD in the three ethnicities relevant to this review; however, three of the studies where data were extracted were not included in the meta-analysis as they did not report incidence rates; Chandie Shaw et al 34 and Gerchman et al 47 reported odds of having eGFR rather than incidence rates, and Ali et al 44 reported different clinical outcomes relating to decline in kidney function.
The estimated pooled IRR for ESRD was significantly higher in All Egger's tests for publication bias were nonsignificant, and an examination of the funnel plots raised no concerns for the presence of publication bias. The number of studies included in the metaanalyses models were fairly small, and heterogeneity was high.
| DISCUSSION
This systematic review and meta-analysis of published prevalence studies showed no significant differences in the prevalence of microalbuminuria in South Asian and Afro-Caribbean participants compared with white European participants with T2DM. Of the five studies identified for the present review for various markers of renal impairment progression, when comparing the rates of deterioration between South Asian and white participants, the results were inconsistent, with a preponderance towards a high rate of disease progression in South
Asian compared with white participants. This is consistent with previous studies. 34, 42, 45 Similarly, an inconsistent pattern of renal disease progression rates was found in studies that compared black participants with white participants, but two 42, 44 out of the three studies identified showed a higher rate in black than in white participants.
These results are in keeping with studies assessing the progression of renal disease in people without diabetes. In the observational analysis of combined data from the Third National Health and Nutrition Examination Survey and the US Renal Data System, which includes patients without diabetes, even though the prevalence of CKD was similar among African American and white patients, the estimated progression rates among those with CKD were fivefold higher among the African American patients. 48 It is acknowledged that some of the differences found in the present systematic review for prevalence of microalbuminuria between ethnic groups, may be attributable to differences in age and duration of diabetes by ethnicity. This was review, a beneficial effect of renin-angiotensin-aldosterone system (RAAS) inhibition was noted which is likely to be along the proteinuria axis, as this has been confirmed in other landmark trials. 52, 53 Despite these benefits, other studies have shown that African American patients treated with RAAS therapy continue to progress during the long-term follow-ups. 54 This progression to ESRD could be occurring across other non-albuminuric pathways that remain to be established. 55 Other reasons including genetic predisposition (particularly with recent discovery of apolipoprotein L1), 56 obesity, low socioeconomic status, high-risk health behaviours (such as poor diet), and limited access to healthcare could also account for the continuous Abuaisha (1998) Alharbi (2015) Allawi (1998) Benhalima (2011) Bhalla (2013) Chowdury (2002) Chowdury (2006) Davis (2013) Dixon (2006) Dreyer (2009) Fischbacher (2003) Kou (2017) Levene (2004) Mather (1998) Raymond (2011) Shaw (2006) Risk of microalbuminuria (95% Cl) Weijers (1997) Winkley (2013) Overall (I-squared= 53.0%, p = 0.047)
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Mortality, n (%) Prevalence greater in South Asians Incidence rate greater in African Caribbeans early morning sample. The use of a single ACR value may underestimate microalbuminuria in those with a higher muscle mass, including men and could be affected by variations in diet or physical exercise. 58 The presence of selection bias is another limiting factor which can have a considerable impact on prevalence estimates of the different stages of diabetic nephropathy. Different methods for ascertainment of outcomes were also used in the studies, making this a limiting factor during comparisons.
The number of studies in the present review was limited because seven of the 22 excluded studies were due to lack of differentiation between the types of diabetes as a cause of underlying diabetic nephropathy. This is an important differentiating feature which has been ignored in these studies. Generally, it is estimated that 20% to 30% of people with T1DM develop proteinuria, and a large number progress to renal failure. 59 Fewer patients with T2DM progress to ESRD but, despite this, they account for the large majority of patients on renal units. This is largely attributable to the higher prevalence of T2DM compared with T1DM. Racial differences have also been observed between patients with T1DM with nephropathy and those with T2DM and nephropathy. 12 In conclusion, the present systematic review and meta-analysis of published prevalence studies showed that the pooled estimates of microalbuminuria, were numerically higher in South Asian compared with white European participants, however, these results were not statistically significant. This review was able to identify few studies relating to progression of diabetic nephropathy in South Asian compared with white European participants. Our results were inconsistent with South Asian and African Caribbean participants demonstrating a faster progression than white European participants in some of the studies; however, because there was considerable heterogeneity among these studies, no definite conclusion can be drawn on whether disease progression is significantly different in these individuals. This review found a significantly higher IRR for ESRD in African Caribbean than in white European participants. These results highlight the need for more research on the potential non-albuminuric pathways of progression to ESRD, with a focus on ethnic origin to explore if a correlation between the two exists. This systematic review also revealed the sparsity in studies looking at the progression of diabetic nephropathy in patients with T2DM, which highlights the need for more research studies to determine if ethnic disparities do exist in disease progression and outcomes of T2DM-associated nephropathy that can guide early, targeted interventions and improved healthcare delivery in these high-risk individuals.
